CytomX Therapeutics, Inc.

CytomX Therapeutics Misses on EPS, Stock Down 0.48%

CytomX Therapeutics reported a loss per share of $0.09, which was below expectations, although no revenue figures were disclosed. The stock reacted by declining 0.48%, indicating that investors may be concerned about the lack of guidance and the reported loss. The absence of a detailed earnings call further adds to the uncertainty surrounding the company's future performance.